AKBA
Akebia Therapeutics, Inc.1.6200
+0.0100+0.62%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
FY Q4 '25
Key Stats
Market Cap
429.89MP/E (TTM)
-Basic EPS (TTM)
-0.08Dividend Yield
0%Recent Filings
8-K
Akebia acquires kidney drug asset
Akebia Therapeutics closed its $7.0 million upfront asset purchase of Q32 Bio's Phase 1 complement inhibitor ADX-097 (now AKB-097) on November 28, 2025, targeting rare kidney diseases with a Phase 2 basket trial planned for H2 2026. Total potential milestones hit $582M plus tiered royalties to mid-teens. Cash funds operations at least two years. Milestones hinge on execution.
8-K
Q3 revenues surge on Vafseo
Akebia Therapeutics posted Q3 net product revenues of $56.8 million, up from $35.6 million last year, with Vafseo contributing $14.3 million since its January launch. DaVita's pilot wraps in Q4, targeting 275,000 patient accesses by year-end. ASN data showed Vafseo beating ESAs on mortality-hospitalization composite. Cash at $166.4 million funds profitability push, but non-dialysis label shelved.
10-Q
Q3 FY2025 results
Akebia swung to Q3 operating income of $4.4M from a $12.5M loss y/y, fueled by product revenue jumping 60% y/y to $56.8M (Vafseo $14.3M since Jan 2025 launch; Auryxia $42.5M despite Mar 2025 LoE). Gross margins strengthened as Auryxia intangible amortization ended, though COGS rose 82% y/y to $9.4M on higher volumes. Cash swelled to $166.4M on $36.9M operating cash flow, bolstering liquidity against $47.6M BlackRock term debt (11% rate, due 2028). BlackRock covenants met. YTD net income $6.9M vs $46.6M loss y/y. EPS reconciles. Generic Auryxia entry looms.
8-K
Scraps VALOR trial after FDA
Akebia Therapeutics disclosed on October 28, 2025, that FDA feedback from a Type C meeting rejected alignment on the VALOR trial design for vadadustat in late-stage CKD non-dialysis patients, requiring far more patients, time, and cost. The company scrapped VALOR plans and a broad Vafseo label for this group. Dialysis focus intact. Forward risks loom large.
8-K
Vafseo revenues climb to $13.3M
Akebia Therapeutics reported Q2 2025 net product revenues of $60.5 million, up from $41.2 million last year, fueled by Vafseo's $13.3 million launch sales that surged 55% in prescriptions from Q1. DaVita kicks off a pilot across 100+ clinics this month, while USRC wrapped enrollment in the VOICE trial eyeing non-inferiority to ESAs. Cash hit $137.3 million, backing label expansions. Momentum builds, yet generic threats loom for Auryxia.
IPO
Website
Employees
Sector
Industry
ACAD
ACADIA Pharmaceuticals Inc.
26.80-0.46
AKRO
Akero Therapeutics, Inc.
54.65+0.00
ATXI
Avenue Therapeutics, Inc.
0.67+0.02
ATXS
Astria Therapeutics, Inc.
12.87-0.05
CYCN
Cyclerion Therapeutics, Inc.
1.53-0.07
FGEN
FibroGen, Inc
9.51-0.53
KROS
Keros Therapeutics, Inc.
21.53+0.30
TAK
Takeda Pharmaceutical Company L
14.53-0.08
TLPH
Talphera, Inc.
1.20+0.02
VRTX
Vertex Pharmaceuticals Incorpor
454.96-0.75